



Scottish Government Riaghaltas na h-Alba gov.scot

Coronavirus (COVID-19): guidance on treating patients Guidance from the Chief Medical Officer (CMO)

COVID-19 position statement: CPAP for COVID-19-related respiratory failure

Date first published: 18/05/2020

Date first published: 18/05/2020 Publication date of this version: 09/09/2020 Version number: 2.0

Summary of revisions

Date	Version	Revisions
18/05/20	1	Original version
09/09/20	2	Recommendations : Point 2 – 'FFP/N95 mask' changed to 'FFP respirator'; Point 8 – wording revised to emphasise that Health Protection Scotland guidance should be followed
		Section 1.1 , paragraph 4 – wording revised as for Point 8, above; paragraph 5 - new statement and reference to UK-wide advice on infection prevention and control added.

COVID-19 position statement: CPAP for COVID-19-related respiratory failure

Contents

Over	view	1
Reco	mmendations	2
1	Use of CPAP	3
1.1	CPAP in patients with COVID-19	3
1.2	Procurement issues	3
2	Methodology	4
2.1	Updating the guidance	4
2.2	Contributors	4
2.3	Peer review	4
2.4	Editorial review	4
Appe in pa	endix 1: Example standard operating procedure for CPAP atients with COVID-19 pneumonia	5
Refe	rences	6



Overview

The purpose of this document is to provide NHSScotland with advice on the appropriate use of continuous positive airway pressure (CPAP) for patients with COVID-19.

This guideline is for:

- health and care practitioners
- health and care staff involved in planning and delivering services
- national procurement teams.

The recommendations are based on:

- Scottish Thoracic Society Position Statement: CPAP for COVID-19 related respiratory failure (16.04.20)¹
- advice from respiratory physicians with an interest in ventilation support and intensive care specialists working in NHSScotland.

These recommendations have been developed in response to the COVID-19 pandemic situation and so have not followed the standard process used by SIGN to develop guidelines. The recommendations are based on available evidence and expert opinion, with fast expert peer review as assurance.

This guidance will be reviewed and updated as new evidence emerges.

COVID-19 position statement: CPAP for COVID-19-related respiratory failure

Recommendations

- Facilities and the associated staffing model required to provide CPAP therapy in high dependency or hi-care ward settings should be explored to enhance and expand critical care and respiratory medicine COVID-19 surge response capability.
- Session respiratory PPE (gloves, gown, FFP respirator mask, visor) is currently recommended by Health Protection Scotland for use in ward areas where CPAP/NIV is being undertaken. Health Protection Scotland guidance should be reviewed regularly to ensure local protocols are up to date.
- CPAP therapy is usually "oxygen neutral" with regard to provision but oxygen provision capacity across and within hospital sites is an important consideration.
- The creation of site-specific SOPs for CPAP for people with COVID-19 pneumonia is recommended. *See Appendix 1*
- Local team familiarity with equipment is the most important consideration for device, mask and circuit choice for CPAP provision.
- Droplet spread risk is reduced by use of non-vented mask-circuits where use of these is familiar and available.
- Local appraisal of all of these factors will determine site-specific capacity for CPAP provision, and also the clinical scenarios (bridging or deferral of intubation, weaning, ceiling of care) for which CPAP can be safely provided.
- CPAP is regarded as an AGP, and Health Protection Scotland guidance should be followed with local infection control team advice sought on appropriate PPE and safe location to provide this treatment.

1 Use of CPAP

Continuous positive airway pressure (CPAP) treatment delivered via face mask and simple device is widely used for home management of obstructive sleep apnoea syndrome.

Evolving European and UK experience notes benefit from CPAP treatment for carefully selected patients with COVID-19-related pneumonia, as part of bridging, deferral, weaning and possibly ceiling of care breathing-support strategies. This is rapidly evolving and further information will emerge.

General considerations for provision of acute CPAP treatment are similar to those for acute non-invasive ventilation (NIV), which is widely used for periods of hours to a few days in acute wards, respiratory wards and high-dependency units. There are important COVID-19 specific considerations including PPE, monitoring of patients for deterioration and timely escalation and feasibility of safe and good-quality provision of CPAP for patients with COVID-19 pneumonia, with all required ancillary care for extended treatment periods.

1.1 CPAP in patients with COVID-19

A proportion of patients with COVID-19 pneumonia-acute respiratory distress syndrome (ARDS) have CPAP-responsive hypoxaemia. Other institutions and territories have produced position statements endorsing CPAP treatment in COVID-19 pneumonia.²

CPAP therapy for COVID-19 respiratory failure achieves FiO_2 of 50–60% with pressure of 10– 15 cm H₂O and 10–15 L/minute entrained oxygen flow. A non-rebreather mask also requires 10–15 L/minute, so CPAP therapy will usually be "oxygen neutral".

Additional considerations for CPAP COVID-19 management include fluid management, enteral nutrition, thromboprophylaxis and vigilance for thrombotic complications, prone positioning, pressure care, bowel management, symptom-control strategy and risk of delayed recognition of deterioration and/or development of patient-induced lung injury with high-minute ventilations on CPAP.

CPAP is regarded as an aerosol generating procedure (AGP), and Health Protection Scotland guidance should be followed and local infection control team advice on appropriate PPE and safe location to provide this treatment is recommended.

UK-wide advice for infection prevention and control (IPC) for health and care organisations as the UK moves to remobilise healthcare services is also relevant.

1.2 Procurement issues

Extensive benchmarking work has been done by ventilation centres in Glasgow, Edinburgh and Dundee to define optimum device and circuit setup and determine what $CPAP/FiO_2$ therapy can be obtained with the range of equipment available in NHSScotland.

Providing CPAP treatment for patients with COVID-19 pneumonia safely will require close collaboration between respiratory and ICU teams at all NHSScotland acute sites, to determine capacity including staffing, training, location of care and treatment escalation plans.

NHSScotland's national procurement team has moved rapidly to obtain suitable equipment for CPAP provision at national scale during the COVID-19 surge.

Nationally procured equipment for CPAP will be distributed based on availability, local capacity and caseload.

2 Methodology

This Guidance has been produced on behalf of the Scottish Government's Chief Medical Officer in response to the COVID-19 pandemic situation and so has not followed the standard process used by SIGN to develop guidelines. The recommendations are based on expert opinion, with rapid expert peer review as assurance.

2.1 Updating the guidance

This guidance will be considered for review when significant new evidence emerges.

2.2 Contributors

Dr David Anderson	Consultant Respiratory Physician, NHS Greater Glasgow & Clyde
Ms Beatrice Cant	Programme Manager, SIGN
Dr Christopher Carlin	Consultant Respiratory Physician, NHS Greater Glasgow & Clyde
Dr Tom Mackay	Consultant Respiratory Physician, Royal Infirmary of Edinburgh

2.3 Peer review

This document was reviewed by the following:

Clinical Guidance Cell

2.4 Editorial review

As a final quality check, the guideline was reviewed by an editorial group, as follows:

Professor Tom Evans	Professor of Molecular Microbiology, Institute of Infection, Immunity & Inflammation, University of Glasgow and Consultant Infectious Disease Physician, NHS Greater Glasgow & Clyde
Dr Roberta James	Programme Lead, SIGN
Dr Safia Qureshi	Director of Evidence, Healthcare Improvement Scotland

COVID-19 position statement: CPAP for COVID-19-related respiratory failure

Appendix 1:

Example standard operating procedure for CPAP in patients with COVID-19 pneumonia³

	and Clyde
CPAP t	rial
Establis	h treatment escalation plan: is CPAP trial bridging or ceiling of care?
Conside • Incr • Incr	er CPAP trial if sustained oxygen requirement 40-60% with :- eased respiratory rate - observe during conversation. Is breathlessness affecting ability to eat+drink? mplete response to time prone or unable to prone
Care bu Clinical	ndle: time prone, hydration, oral hygiene, nutrition, thromboprophylaxis/thrombovigliance, antibiotics if indicated. trial if eligible.
Review • Cor • Esc	initial response Itinue: if improved oxygenation / work of breathing > with treatment breaks and encourage regular 2 hour CPAP spells alate: if unimproved oxygenation / persting high work of breathing
Prepar	ation
PPE che	ick
2 clinicia Plan to r	Ins prepared for setup Indertake any other clinical care at same contact
Review	device, mask fit, circuit assembly and oxygen connection supporting videos or documentation, if required.
Select r Select c Setup a Ensure Check ı	nask Size to patient using packaging guide. Good mask fit is priority. Use non-vented mask when available. ircuit appropriate for mask. If using non-vented mask, expiratory valve is required as per circuit diagram. nd check device and set initial CPAP pressure 12 all oxygen connections and tubing nonitoring equipment
CPAP	setup
Preferre	d device: A40, Nippv3, A10 or Lumis 100/150.
If near c	ontinuous use >12 hours rotate device if possible, particularly if A10/Lumis.
Establis Titrate of CPAP ti and imp Change	h mask fit and tolerance xygen to maintain target - accepted SpO2 for patient. Higher flow rates typically required with higher CPAP pressures. tration: not usually neccesary but can try vary 10 - 18cmH20 to determine optimum for tolerance, improved oxygenation roved work of breathing. antimicrobial filter after total of 24 hours of circuit usage.
	Patient Patient Oxygen Filter Filter Valve Tubing Humidifier Consider after >12 hours use PAP Device
Humidi	Patient Oxygen mask Filter Expiratory valve rif using non-vented mask* Tubing Humidifier consider after >12 hours use PAP Device fier
Humidi Aim to a initial se	Patient Oxygen Connector Filter Expiratory valve *if using non-vented mask* Tubing Humidifier consider after >12 hours use PAP Device fier dd in humidfier to all patients established on briding/ceiling of care CPAP or NIV if >12 hours use anticipated following tup. Site of the set of the
Humidi Aim to a initial se	Image: Patient Image
Humidi Aim to a initial se Additic Clinical Availabl	Image: Patient Image
Humidi Aim to a initial se Additic Clinical Availabl Videos: bit.ly/NH	Image: Patient Image
Humidi Aim to a initial se Additic Clinical Availabl Videos: bit.ly/NH Device bit.ly/NH	Image: Connector of the co
Humidi Aim to a initial se Additic Clinical Availabl Videos: bit.ly/NF Device bit.ly/NF	Image: Construction of the construc

References

- 1 Scottish Thoracic Society. Position Statement: CPAP for COVID-19-related respiratory failure. 16 April 2020
- 2 NHS England and NHS Improvement. Guidance for the role and use of non-invasive respiratory support in adult patients with COVID19 (confirmed or suspected). [cited 15 May 2020]. Available from url: https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/specialty-guide-NIVrespiratory-support-and-coronavirus-v3.pdf
- **3** NHS Greater Glasgow and Clyde. QEUH respiratory medicine COVID-19 respiratory failure managment, SOP for CPAP in patients with COVID-19 pneumonia. 13 April 2020